The DOI matches its Crossref record.
Nifedipine: Kinetics and dynamics in healthy subjects
Abstract
Kinetics and pharmacologic effects of three formulations of nifedipine were examined in six healthy young men in a crossover design. Each subject received intravenous nifedipine, 0.015 mg/kg body weight, 20 mg in a capsule, and 20 mg in a slow-release tablet. Changes in heart rate (HR), blood pressure, heart dimensions, and plasma norepinephrine levels (PNE) were examined serially. Plasma concentrations of nifedipine (Cp) and urinary metabolite concentrations were measured by liquid chromatography. After intravenous injection the elimination t½ was 1.7 ± 0.4 hr, systemic clearance was 26.7 ± 5.4 l/hr, and volume of distribution was 0.8 ± 0.2 l/kg. After the capsule, Cp rose rapidly, to a maximum concentration (Cmax) of 117 ± 15 ng/ml at a maximum time (tmax) of 1.4 ± 0.5 hr. After the sustained release tablet tmax was 4.2 ± 0.7 hr and Cmax was 26 ± 10 ng/ml. Nifedipine bioavailability was 56% ± 25% for the capsule and 52% ± 13% for the tablet, but there were large interindividual differences. Urinary excretion was 58% ± 13% 24 hr after intravenous injection, and after 32 hr was 55% ± 13% after capsules and 32% ± 8% after tablets. HR increased briefly after intravenous injection and after capsules (15 to 20 bpm), but not significantly after tablets. Diastolic blood pressure (DBP) fell briefly after capsules (8 to 10 mm Hg), but there was a sustained effect after tablets. Cardiac dimensions were unchanged. PNE levels paralleled plasma drug levels in the three experiments. There was a hyperbolic correlation between nifedipine Cp and changes in DBP (r2 = 0.86), with a minimal effective concentration of about 15 ng/ml. It is concluded that nifedipine kinetics correlate directly with the effect on blood pressure and HR. Side effects from a high Cmax can be avoided with the tablet. It is likely that twice-daily dosing will induce a continued effect. Clinical Pharmacology and Therapeutics (1984) 35, 742–749; doi:10.1038/clpt.1984.105
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorkin, E. M., Clissold, S. P., & Brogden, R. N. (1985) · Drugs · doi:10.2165/00003495-198530030-00002 · Cited by 355
Formulation approaches in enhancement of patient compliance to oral drug therapy
Shahiwala, A. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.628311 · Cited by 84
Novel Oral Drug Formulations: Their Potential in Modulating Adverse Effects
Florence, A. T., & Jani, P. U. (1994) · Drug Safety · doi:10.2165/00002018-199410030-00005 · Cited by 84
Toal, C. B., Meredith, P. A., & Elliott, H. L. (2012) · Blood Pressure · doi:10.3109/08037051.2012.690615 · Cited by 64
Hansmann, S., Darwich, A., Margolskee, A., Aarons, L., & Dressman, J. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12618 · Cited by 38
Metadata
- Authors
- Kleinbloesem, C. H., van Brummelen, P., Van De Linde, J. A., Voogd, P. J., & Breimer, D. D.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1984-06
- Volume
- 35
- Issue
- 6
- Pages
- 742-749
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2071092830
- Cited by
- 223
- References
- 0
- FWCI
- 13.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nifedipine: Kinetics and dynamics in healthy subjects. https://app.cochat.ai/papers/10.1038/clpt.1984.105
- The paper
- Kleinbloesem, C. H., van Brummelen, P., Van De Linde, J. A., Voogd, P. J., & Breimer, D. D. (1984). Nifedipine: Kinetics and dynamics in healthy subjects. Clinical Pharmacology and Therapeutics. https://doi.org/10.1038/clpt.1984.105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.